Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Efficacy of Fremanezumab in Patients With Lower and Higher Frequency Chronic Migraine
Headache
Headache Posters (7:00 AM-5:00 PM)
024

Increasing frequency of migraine attacks is associated with greater burden and more difficult-to-treat disease. Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP), has been approved for the preventive treatment of migraine in adults. This pooled analysis evaluated the efficacy of fremanezumab in patients with higher-frequency CM (HFCM; ≥19 migraine days/month) and lower-frequency CM (LFCM; 15-18 days/month).

This pooled analysis evaluated efficacy of fremanezumab in patients with chronic migraine (CM) by category of baseline migraine frequency.

This analysis included patients with CM from 2 double-blind phase 3 trials (HALO CM and FOCUS [included patients with inadequate response to 2-4 prior preventive treatment classes]). Patients were randomized 1:1:1 to quarterly fremanezumab (Months 1/2/3: 675mg/placebo/placebo), monthly fremanezumab (675mg/225mg/225mg), or placebo for 12 weeks. Changes in monthly average migraine days (MMDs) and headache days of at least moderate severity (MHDs) and proportions of patients with ≥50% reduction in MMD were evaluated in patients with LFCM and HFCM at baseline.

A total of 511 patients had LFCM and 500 had HFCM at baseline. With fremanezumab versus placebo, significantly greater least-squares mean(SE) reductions from baseline over 12 weeks were observed in patients with both HFCM and LFCM in MMDs (LFCM: quarterly, −5.9[0.50]; monthly, −5.9[0.48] vs placebo, −3.2[0.51]; HFCM: quarterly, −4.6[0.52]; monthly, −5.5[0.52] vs placebo, −2.9[0.52]; all P≤0.0078) and MHDs (LFCM: quarterly, −4.9[0.44]; monthly, −5.3[0.43] vs placebo, −2.2[0.46]; HFCM: quarterly, −4.6[0.50]; monthly, −5.4[0.49] vs placebo, −2.5[0.50]; all P≤0.0007). Proportions of patients with ≥50% reduction in MMDs were also significantly higher with fremanezumab versus placebo in patients with LFCM (quarterly, 34%; monthly, 31% vs placebo, 16%) and HFCM (quarterly, 18%; monthly, 23% vs placebo, 10%; all P≤0.0464).

Fremanezumab demonstrated efficacy for CM, based on reductions in MMDs and MHDs versus placebo, regardless of baseline migraine frequency.

Authors/Disclosures
Peter J. McAllister, MD, FAAN (New England Inst for Neurology and Headache)
PRESENTER
Dr. McAllister has received personal compensation for serving as an employee of Revance. Dr. McAllister has received personal compensation for serving as an employee of AbbVie. Dr. McAllister has received personal compensation for serving as an employee of Merz. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aeon. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for lilly. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for teva. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for abbvie. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for biohaven. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for lundbeck.
Joshua *use 125685 Cohen (Teva Pharmaceuticals Industries) Joshua Cohen has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Xiaoping Ning (Teva pharmaceuticals) Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical . Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical.
Verena *use 212969 Ramirez Campos (Teva Pharmaceuticals) Verena Ramirez Campos has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Nahum Nesher (Tel Aviv Medical Center) Steve Barash has received personal compensation for serving as an employee of Teva. Steve Barash has received stock or an ownership interest from Teva.
Messoud Ashina, MD, PhD (Dept. of Neurology) Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer.